Zurcher Kantonalbank Zurich Cantonalbank Boosts Stake in Embecta Corp. (NASDAQ:EMBC)

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Embecta Corp. (NASDAQ:EMBC) by 29.4% in the 4th quarter, Holdings Channel reports. The firm owned 15,003 shares of the company’s stock after buying an additional 3,411 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Embecta were worth $284,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of EMBC. SG Americas Securities LLC bought a new stake in shares of Embecta during the 3rd quarter worth approximately $450,000. Raymond James & Associates increased its holdings in Embecta by 1,129.2% during the third quarter. Raymond James & Associates now owns 160,793 shares of the company’s stock valued at $2,420,000 after buying an additional 147,712 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Embecta by 2.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,564 shares of the company’s stock valued at $460,000 after buying an additional 834 shares during the period. Allspring Global Investments Holdings LLC raised its stake in Embecta by 371.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 50,837 shares of the company’s stock worth $765,000 after buying an additional 40,056 shares in the last quarter. Finally, Allworth Financial LP lifted its holdings in Embecta by 200.1% during the third quarter. Allworth Financial LP now owns 3,280 shares of the company’s stock worth $49,000 after buying an additional 2,187 shares during the period. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Insider Activity at Embecta

In other news, Director David F. Melcher purchased 2,000 shares of the business’s stock in a transaction on Monday, February 12th. The shares were acquired at an average cost of $16.25 per share, with a total value of $32,500.00. Following the completion of the acquisition, the director now owns 45,080 shares of the company’s stock, valued at $732,550. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.28% of the stock is currently owned by corporate insiders.

Embecta Trading Down 0.8 %

Shares of NASDAQ:EMBC opened at $10.15 on Monday. The company has a market capitalization of $584.44 million, a PE ratio of 10.68 and a beta of 0.86. Embecta Corp. has a 12-month low of $9.93 and a 12-month high of $32.00. The business’s fifty day simple moving average is $12.28 and its 200-day simple moving average is $15.24.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Friday, February 9th. The company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.15. The company had revenue of $277.30 million for the quarter, compared to the consensus estimate of $264.92 million. Embecta had a negative return on equity of 18.66% and a net margin of 4.93%. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter last year, the company earned $0.93 earnings per share. Research analysts predict that Embecta Corp. will post 2.14 EPS for the current year.

Embecta Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Wednesday, February 28th were paid a dividend of $0.15 per share. The ex-dividend date of this dividend was Tuesday, February 27th. This represents a $0.60 annualized dividend and a dividend yield of 5.91%. Embecta’s dividend payout ratio (DPR) is presently 63.16%.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.